Volume | 490,499 |
|
|||||
News | - | ||||||
Day High | 2.58 | Low High |
|||||
Day Low | 2.445 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Emergent Biosolutions Inc | EBS | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.52 | 2.445 | 2.58 | 2.53 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,003 | 490,499 | $ 2.51 | $ 1,230,404 | - | 1.81 - 16.6643 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:08:16 | 100 | $ 2.445 | USD |
Emergent Biosolutions Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.67B | 51.81M | - | 1.12B | -223.8M | -4.32 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Emergent Biosolutions News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EBS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.18 | 2.665 | 2.01 | 2.38 | 1,700,016 | 0.265 | 12.16% |
1 Month | 2.12 | 2.665 | 1.81 | 2.16 | 1,450,801 | 0.325 | 15.33% |
3 Months | 4.01 | 4.29 | 1.81 | 2.80 | 1,693,486 | -1.57 | -39.03% |
6 Months | 8.07 | 9.96 | 1.81 | 4.76 | 1,934,181 | -5.63 | -69.7% |
1 Year | 12.12 | 16.6643 | 1.81 | 7.35 | 1,684,091 | -9.68 | -79.83% |
3 Years | 83.46 | 127.20 | 1.81 | 26.64 | 1,029,940 | -81.02 | -97.07% |
5 Years | 69.10 | 137.61 | 1.81 | 38.08 | 827,075 | -66.66 | -96.46% |
Emergent Biosolutions Description
Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products. |